Warning Misonix, Inc. (MSON) pessimists! Patrick Mcbrayer just Acquired 1,000 shares.; BONTERRA ENERGY CORPORATION (BNEFF) SI Decreased By 3.05%

BONTERRA ENERGY CORPORATION (OTCMKTS:BNEFF) had a decrease of 3.05% in short interest. BNEFF’s SI was 626,000 shares in February as released by FINRA. Its down 3.05% from 645,700 shares previously. With 8,700 avg volume, 72 days are for BONTERRA ENERGY CORPORATION (OTCMKTS:BNEFF)’s short sellers to cover BNEFF’s short positions. The stock increased 9.16% or $0.9 during the last trading session, reaching $10.69. About 300 shares traded. Bonterra Energy Corp (OTCMKTS:BNEFF) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Today, the director of Misonix Inc, Mr. Patrick Mcbrayer, acquired 1,000 shares, totalling $10,540 U.S Dollars, based on $10.5 for a share. he currently holds 0.01% of the total market capitalization of the Company.

Bonterra Energy Corp., an upstream oil and gas company, engages in the production and sale of crude oil, natural gas, and natural gas liquids. The company has market cap of $349.91 million. It primarily focuses on the development of its Cardium land within the Pembina and Willesden Green areas located in central Alberta. It currently has negative earnings. The firm also holds interests in the Shaunavon area in Saskatchewan, and the Prespatou area of northeast British Columbia.

Misonix, Inc., together with its subsidiaries, designs, develops, makes, and markets therapeutic ultrasonic medical devices in the United States and internationally. The company has market cap of $95.06 million. The firm offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells, as well as other medical devices. It currently has negative earnings. The Company’s products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wounds, and maxillo-facial applications.